InVivo Therapeutics Holdings (FRA:04I) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is InVivo Therapeutics Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. InVivo Therapeutics Holdings's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.00.

InVivo Therapeutics Holdings's long-term debt to total assets ratio declined from Sep. 2022 (0.05) to Sep. 2023 (0.00). It may suggest that InVivo Therapeutics Holdings is progressively becoming less dependent on debt to grow their business.

InVivo Therapeutics Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for InVivo Therapeutics Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InVivo Therapeutics Holdings LT-Debt-to-Total-Asset Chart

InVivo Therapeutics Holdings Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.11

0.03

0.04

0.03

InVivo Therapeutics Holdings Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.03	0.03	0.02	-

InVivo Therapeutics Holdings LT-Debt-to-Total-Asset Calculation

InVivo Therapeutics Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	0.522	/	17.768
	=

InVivo Therapeutics Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )	/	Total Assets (Q: Sep. 2023 )
	=	0	/	8.98
	=

InVivo Therapeutics Holdings (FRA:04I) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

InVivo Therapeutics Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

InVivo Therapeutics Holdings (FRA:04I) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (FRA:04I) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

NVIV:USA

Address

One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139

Website

https://www.invivotherapeutics.com

InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.

InVivo Therapeutics Holdings (FRA:04I) Headlines

No Headlines